Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children-Reference-Cited by-同舟云学术

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children

Published:2021-11-16 Issue:11 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Garegnani Luis¹,Styrmisdóttir Lea²,Roson Rodriguez Pablo³,Escobar Liquitay Camila Micaela⁴,Esteban Ignacio⁵⁶,Franco Juan VA¹

Affiliation:

1. Associate Cochrane Centre; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina

2. Faculty of Medicine; Lund University; Lund Sweden

3. Research Department; Instituto Universitario Hospital Italiano; Buenos Aires Argentina

4. Central Library; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina

5. Fundación INFANT; Buenos Aires Argentina

6. Pediatric Stepdown Unit; Hospital Italiano de Buenos Aires; Buenos Aires Argentina

Publisher

Wiley

Subject

Pharmacology (medical)

Reference127 articles.

1. Blanken M Rovers M Molenaar J Winkler-Seinstra P Meijer A Kimpen J Respiratory syncytial virus prevention with Palivizumab is associated with a decrease in non-hospitalized RSV infections; 2013 May 4 - 7; Washington, D.C Pediatric Academic Societies Annual Meeting 2013

2. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks;Blanken;Contemporary Clinical Trials,2012

3. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants;Blanken;European Journal of Pediatrics,2018

4. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants;Blanken;New England Journal of Medicine,2013

5. Causal relationship between respiratory syncytial virus infection and recurrent wheeze during the first year of life;Bont;American Journal of Respiratory and Critical Care Medicine,2013

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating immunoinformatics and computational epitope prediction for a vaccine candidate against respiratory syncytial virus;Infectious Disease Modelling;2024-09

2. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study;The Lancet Regional Health - Europe;2024-09

3. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants;50 Studies Every Neonatologist Should Know;2024-09

4. Impact of respiratory syncytial virus on older children: Exploring the potential for preventive strategies beyond the age of 2 years;Vaccine;2024-08

5. Impacto de la inmunización con nirsevimab en las infecciones por VRS atendidas en urgencias pediátricas: primeros resultados en un hospital terciario de Madrid;Enfermedades Infecciosas y Microbiología Clínica;2024-08